SCHEMBL21136735

SCHEMBL21136735

CC(C)(C)OC(=O)N1CCN(c2c([N+](=O)[O-])cnc3c(F)c(Br)c(Cl)cc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.47
MAPT P10636 6/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 4/20 0.43
MET P08581 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.38
MAPK8 P45983 1/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
MAPK1 P28482 1/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
GPR174 Q9BXC1 1/20 0.36
POLB P06746 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21136903 0.87 ALDH1A1 (0.40) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL28681459 0.87 KCNH2 (0.38) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL16636900 0.85 MAPK8 (0.39) KCNH2MAPTSMN1; SMN2MAPK8GPR119
SCHEMBL30998001 0.85 MAPT (0.46) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL27094352 0.85 MAPT (0.46) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL21099594 0.85 KCNH2 (0.37) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL28648177 0.85 KCNH2 (0.37) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL21099600 0.85 KCNH2 (0.37) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL21136780 0.85 KCNH2 (0.37) KCNH2MAPTALDH1A1LMNAMET
SCHEMBL16636974 0.85 MAPK8 (0.39) KCNH2MAPTSMN1; SMN2MAPK8GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019110751-A1 TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2019-06-13 WO disclosed